Currently Viewing:
American Society of Clinical Oncology (ASCO) 2017
Dr Barbara McAneny on How the COME HOME Model Helps Cut Hospitalization Rates
June 14, 2017
Real-World Treatment Patterns Highlight Need for Clinical Education on PD-L1 Testing in NSCLC
June 13, 2017
Can the 4 Ps Devise Interventions to Reduce the Financial Toxicity of Cancer?
June 06, 2017
Dr Barbara McAneny Outlines Collaboration With ASCO on COME HOME Model
June 05, 2017
Daratumumab With Standard Regimen Improves PFS in Multiple Myeloma, Independent of Cytogenetic Risk
June 05, 2017
MACRA 2.0 and Beyond: Preparing Your Practice to Meet the Quality and Reporting Challenges
June 05, 2017
Currently Reading
Dr Craig Portell Highlights New and Exciting Treatments for Non-Hodgkin's Lymphoma
June 05, 2017
Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer
June 04, 2017
Do We Have Adequate Surveillance in Cancer Survivor Care?
June 04, 2017
Dr Basit Chaudhry on Experiences in the Oncology Care Model and Early Indications of Success
June 04, 2017
Dr Scott Ramsey: Value Frameworks Are Moving Toward Harmonization
June 03, 2017
Physician, Regulatory, and Payer Perspectives on the Value of Real-World Data
June 03, 2017
Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC
June 03, 2017
Dr Daniel George Highlights Successes of Checkpoint Inhibitors in Prostate, Bladder Cancers
June 03, 2017
ASCO Study Finds Shift in Diagnosis Stage for Several Cancers Following ACA Implementation
June 01, 2017
HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults
May 31, 2017

Dr Craig Portell Highlights New and Exciting Treatments for Non-Hodgkin's Lymphoma

Craig Portell, MD, of the University of Virginia Health System, highlights some of the latest and most exciting treatments in non-Hodgkin's lymphoma, including CAR-T therapies and targeted therapies such as venetoclax.


Craig Portell, MD, of the University of Virginia Health System, highlights some of the latest and most exciting treatments in non-Hodgkin's lymphoma, including CAR-T therapies and targeted therapies such as venetoclax.

Transcript

What is the latest in treatments for non-Hodgkin's lymphoma?

There are many new and exciting treatments for non-Hodgkin's lymphoma that are coming up. Some of them are changing the standard rituximab antibody, doing new novel ways of targeting CD20 in non-Hodgkin's lymphoma. Some of them are having very good outcomes and prolonging progression-free survival when compared to rituximab.

There's also cellular therapies such as CAR therapy where patients' own T cells are activated and stimulated to attack non-Hodgkin's lymphoma cells as well as other normal B cells. It's kind of targeted way of doing an allogeneic stem cell transplant. Those are labor intensive and difficult to do but as we move forward in the field, as it gets easier to do, I think those are going to be very promising.

Of course, we also have many small molecule targeted therapies that are becoming increasingly used in non-Hodgkin's lymphoma, including ibrutinib, idelalisib, and any of the other targeted therapies in the B-cell receptor pathway. Finally, one of the more exciting drugs in targeted therapy is venetoclax. We just recently had a publication out of Journal of Clinical Oncology, which showed efficacy of venetoclax; how we use it and where we use it, and monitoring for tumor lysis is very important when we move to using venetoclax more and more in non-Hodgkin's lymphoma.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!